The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.
The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.
复制标题
阿托伐醌对急性淋巴细胞白血病儿童依托泊苷药代动力学的影响。
DOI：
10.1007/s002800000250
复制
发表时间：
2001
影响因子：
3
通讯作者：
Flynn,PM
中科院分区：
文献类型：
--
作者：
vandePoll,ME;Relling,MV;Schuetz,EG;Harrison,PL;Hughes,W;Flynn,PM
Purpose:The use of trimethoprim/sulfamethoxazole in the prevention ofPneumocystis cariniipneumonia in patients with acute lymphoblastic leukemia (ALL) may cause undesirable adverse effects: fungal overgrowth, neutropenia, and drug resistance. A possible alternative is atovaquone, a hydroxynaphthoquinone with anti-Pneumocystis cariniiactivity. However, it is not known if atovaquone alters the disposition or adverse effects of antileukemic drugs.Methods:Using a crossover study design, we compared the pharmacokinetics of etoposide and its CYP3A4-formed catechol metabolite when given as a 300 mg/m2i.v. infusion following daily atovaquone versus trimethoprim/sulfamethoxazole in nine patients.Results:The area under the concentration time curve (AUC) of etoposide, etoposide catechol and the catechol to etoposide AUC ratio were slightly higher (a median of 8.6%, 28.4%, and 25.9%) following atovaquone as compared to trimethoprim/sulfamethoxazole (P=0.055,P=0.031 andP=0.023), respectively. In vitro analysis in human liver microsomes showed modest inhibition of etoposide catechol formation in the presence of atovaquone. Using uptake of3H-vinblastine in L-MDR1 cells, atovaquone was shown to inhibit P-glycoprotein with an apparent Ki of 95.6 µM.Conclusions:Although the effect of atovaquone on etoposide disposition was modest, in light of the fact that the risk of etoposide-related secondary acute myeloid leukemia has been linked to minor changes in schedule and concurrent therapy, we suggest caution with the simultaneous administration of atovaquone and etoposide, particularly if used with other CYP3A4/P-glycoprotein substrates.
